GTCM
RPRX icon

Gyon Technologies Capital Management’s Royalty Pharma RPRX Stock Holding History

Gyon Technologies Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2
Closed -$79 – 333
2022
Q4 		$79 Buy
+2
New +$83 ﹤0.01% 480
2022
Q1 		– Sell
-5,894
Closed -$235K – 524
2021
Q4 		$235K Buy
+5,894
New +$229K 0.04% 471

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gyon Technologies Capital Management's RPRX Position: Q1 2023 in Review

Gyon Technologies Capital Management sold out of Royalty Pharma (RPRX) in Q1 2023, closing a stake of 2 shares — an estimated $79 sold.

Gyon Technologies Capital Management first reported a position in RPRX in Q4 2021 and held it in 2 quarters. The position peaked at $235K in Q4 2021. 335 funds tracked by Wall St. Rank hold RPRX as of Q1 2023.

  • Gyon Technologies Capital Management reported no remaining Royalty Pharma position as of Q1 2023 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 2 Royalty Pharma shares in Q1 2023, an estimated $79.
  • Gyon Technologies Capital Management first reported a position in Royalty Pharma in Q4 2021 and held it in 2 quarters.
  • Gyon Technologies Capital Management's Royalty Pharma position peaked at $235K in Q4 2021.
  • 335 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2023.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2023.